Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink: a case-cross-over study.

ABSTRACT:

Background and aims

Varenicline and nicotine replacement therapy (NRT) are the most commonly used medications to quit smoking. Given their widespread use, monitoring adverse risks remains important. This study aimed to estimate the neuropsychiatric and cardiovascular risks associated with varenicline and NRT as used in routine UK care.

Design

Case-cross-over study.

Setting

UK-based electronic primary care records in the Clinical Practice Research Datalink from 2006 to 2015 linked to hospital and mortality data sets.

Participants

Adult smokers (n =282,429) observed during periods when exposed and not exposed to either varenicline or NRT.

Measurements

Main outcomes included suicide, self-harm, myocardial infarction (MI), all-cause death and cause-specific

SUBMITTER: Thomas KH 

PROVIDER: S-EPMC8246946 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature